Company Filing History:
Years Active: 2024
Title: Sarah Schmitz - Innovator in Microfluidic Technology
Introduction
Sarah Schmitz is an accomplished inventor based in Cologne, Germany. With a focus on advancements in biotechnology, she has made significant contributions to the field, particularly in microfluidics. Her innovative work is underscored by her patent that showcases her expertise in developing solutions to enhance cellular flow through microfluidic channels.
Latest Patents
Sarah Schmitz holds a patent for "Non-specific nucleases from the genus for use in facilitating flow of cells through a microfluidic channel." This invention includes a composition comprising an isolated polypeptide exhibiting non-specific nuclease (NSN) activity that degrades nucleic acids. Specifically, the polypeptide has an amino acid sequence identity of at least 70% to SEQ ID NO:2, with activity present at about 4°C. The composition features a cation complexing agent, such as EDTA, and is preferably neutral to basic in pH. Additionally, the patent encompasses a kit comprising this composition and outlines methods utilizing it.
Career Highlights
Sarah Schmitz's work is primarily associated with Miltenyi Biotec B.V. & Co. KG, a leading company in the biotechnology sector. Her role in the organization has been pivotal in driving forward the company's innovative projects in cellular research and microfluidic applications.
Collaborations
In her professional journey, Sarah has collaborated with notable colleagues, including Skander Elleuche and Stefan Miltenyi, both of whom have been instrumental in advancing the research and application of biotechnological innovations. These collaborations highlight the importance of teamwork in the scientific community and the collective effort toward achieving groundbreaking results.
Conclusion
Sarah Schmitz is a prominent figure in the realm of biotechnology, particularly known for her contributions to microfluidic technology. Her patent reflects her expertise and commitment to scientific advancement, making her a valuable innovator in her field. As she continues her work with Miltenyi Biotec, her future endeavors are anticipated to further influence the biotechnological landscape.